Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011 Aug 11;365(6):518-26. \[[PubMed: 21830966](https://pubmed.ncbi.nlm.nih.gov/21830966)\] 22. DeBiasi EM, Pisani MA, Murphy TE, Araujo K, Kookoolis A, Argento AC, Puchalski J. Mortality among patients with pleural effusion undergoing thoracentesis. Eur Respir J. 2015 Aug;46(2):495-502. \[[PMC free article: PMC4857137](/pmc/articles/PMC4857137/)\] \[[PubMed: 25837039](https://pubmed.ncbi.nlm.nih.gov/25837039)\] 23. Yang Y, Du J, Wang YS, Kang HY, Zhai K, Shi HZ. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis. Clin Transl Sci. 2022 Jun;15(6):1340-1354. \[[PMC free article: PMC9199884](/pmc/articles/PMC9199884/)\] \[[PubMed: 35212454](https://pubmed.ncbi.nlm.nih.gov/35212454)\] 24. Markatis E, Perlepe G, Afthinos A, Pagkratis K, Varsamas C, Chaini E, Papanikolaou IC, Gourgoulianis KI. Mortality Among Hospitalized Patients With Pleural Effusions. A Multicenter, Observational, Prospective Study. Front Med (Lausanne). 2022;9:828783. \[[PMC free article: PMC8907663](/pmc/articles/PMC8907663/)\] \[[PubMed: 35280903](https://pubmed.ncbi.nlm.nih.gov/35280903)\] 25. Shu M, Wang BY, Zhang J, Guo CY, Wang XH. Analysis of specialized nursing on respiratory functions in thoracotomy patients. J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):971-976. \[[PubMed: 29254301](https://pubmed.ncbi.nlm.nih.gov/29254301)\] 26. Lu C, Jin YH, Gao W, Shi YX, Xia X, Sun WX, Tang Q, Wang Y, Li G, Si J. Variation in nurse self-reported practice of managing chest tubes: A cross-sectional study. J Clin Nurs. 2018 Mar;27(5-6):e1013-e1021. \[[PubMed: 29076204](https://pubmed.ncbi.nlm.nih.gov/29076204)\] **Disclosure:** Rachana Krishna declares no relevant financial relationships with ineligible companies. **Disclosure:** Marsha Antoine declares no relevant financial relationships with ineligible companies. **Disclosure:** Mohamed Alahmadi declares no relevant financial relationships with ineligible companies. **Disclosure:** Mohan Rudrappa declares no relevant financial relationships with ineligible companies.